ad image

Community

David Alvaro, Ph.D.
David Alvaro, Ph.D.

Editor in Chief, Pharma's Almanac

David is Scientific Editor in Chief of the Pharma’s Almanac content enterprise, responsible for directing and generating industry, scientific and research-based content, including client-owned strategic content, in addition to working with the Nice Insight research team. Before joining That’s Nice, David served as a scientific editor for the multidisciplinary scientific journal Annals of the New York Academy of Sciences and in several roles in scientific and medical writing, editing, and communication. He received a B.A. in biology from New York University in 1999 and a Ph.D. in genetics and development from Columbia University in 2008, where he worked in the laboratory of Rodney Rothstein, Ph.D., exploring DNA repair and recombination.

106 Contributions1 / 6
Pioneering Breakthroughs in Retinal Disease Treatment
Retinal Disease

Pioneering Breakthroughs in Retinal Disease Treatment

David Alvaro, Ph.D.; David Zacks, M.D., Ph.D.; David Esposito

Pharma's Almanac

PAO-12-23-CL-01Dec 14, 2023
View from the Top: Cell and Gene Therapy Successes and Promise
Cell and Gene Therapy

View from the Top: Cell and Gene Therapy Successes and Promise

David Alvaro, Ph.D.

Pharma's Almanac

PAO-08-23-NI-01Oct 03, 2023
The Powerful Potential of Digital Twin Technology to Improve Drug Discovery, Development, Manufacturing, and More
Digital Twin Technology

The Powerful Potential of Digital Twin Technology to Improve Drug Discovery, Development, Manufacturing, and More

David Alvaro, Ph.D.

Pharma's Almanac

PAO-03-23-NI-02Mar 07, 2023
Unlocking New Possibilities in Research, Therapeutics, and Beyond with Morpholino Antisense Oligos
Gene Tools

Unlocking New Possibilities in Research, Therapeutics, and Beyond with Morpholino Antisense Oligos

David Alvaro, Ph.D.; Jon Moulton, Ph.D.

Pharma's Almanac

PAO-01-23-CL-05Feb 01, 2023
Synthetic Biology: A Potential Game-Changer for the Biopharma Industry
Synthetic Biology

Synthetic Biology: A Potential Game-Changer for the Biopharma Industry

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.

Pharma's Almanac

PAO-12-022-NI-01Dec 23, 2022
Bedside Cell Therapies: Point-of-Care Manufacturing Is Slowly Becoming a Reality
Cell Therapy

Bedside Cell Therapies: Point-of-Care Manufacturing Is Slowly Becoming a Reality

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.

Pharma's Almanac

PAO-11-022-NI-08Nov 15, 2022
Optimizing Transient Transfection for Viral Vector Production
Viral Vector Manufacturing

Optimizing Transient Transfection for Viral Vector Production

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.

Pharma's Almanac

PAO-11-022-NI-09Nov 15, 2022
Ecolab and Pharma’s Almanac Present Contamination Control Event
Contamination Control Event

Ecolab and Pharma’s Almanac Present Contamination Control Event

David Alvaro, Ph.D.

Pharma's Almanac

PAO-11-022-CL-04Nov 15, 2022
Antibiotic Resistance: Advances in Understanding and Drug Development
Antibiotic Resistance

Antibiotic Resistance: Advances in Understanding and Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

PAO-10-022-NI-07Oct 11, 2022
Examining the Potential of Precision/Personalized Medicine
Precision Medicine

Examining the Potential of Precision/Personalized Medicine

David Alvaro, Ph.D.

Pharma's Almanac

PAO-10-022-NI-03Oct 11, 2022
Leveraging Big Data, Artificial Intelligence, and Machine Learning for Drug Discovery, Development, Manufacturing, and More
Big Data

Leveraging Big Data, Artificial Intelligence, and Machine Learning for Drug Discovery, Development, Manufacturing, and More

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.

Pharma's Almanac

PAO-10-022-NI-05Oct 11, 2022
CAR-T Study Shines New Spotlight on Clinical Trials Representation
Column: Clinical Trials

CAR-T Study Shines New Spotlight on Clinical Trials Representation

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-022--NI-06Jul 02, 2022
New Drug Watch: A Validation of the ‘Twincretin’ Approach to Type 2 Diabetes
Column: New Drug Watch

New Drug Watch: A Validation of the ‘Twincretin’ Approach to Type 2 Diabetes

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-022--NI-08Jun 24, 2022
The Price of Pain: Acknowledging a Crisis and Encouraging an Alternative
Column: Regulatory Spotlight

The Price of Pain: Acknowledging a Crisis and Encouraging an Alternative

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-022--NI-05Jun 24, 2022
10 More Biotechs Making Moves in 2022
Biotechs

10 More Biotechs Making Moves in 2022

David Alvaro, Ph.D.; Danielle Alvarez

Pharma's Almanac

PAO-06-022--NI-07Jun 24, 2022
Reducing Time to IND, Increasing Quality, and Building Trust through Shared Data
Digitalization

Reducing Time to IND, Increasing Quality, and Building Trust through Shared Data

David Alvaro, Ph.D.; Christa Short; Jesse McCool, Ph.D.; Lance Johnson; Markus Gershater, Ph.D.; Michael Sokolov, Ph.D.; Yuk Chun Chiu, M.S.E.; Guy Levy-Yurista, Ph.D.; David Schmidt, M.B.A., M.Sc.

Pharma's Almanac

PAO-05-022-CL-01May 18, 2022
Transformative Early and Patient-Centric Treatments for Retinal Diseases
Ophthalmic

Transformative Early and Patient-Centric Treatments for Retinal Diseases

David Alvaro, Ph.D.; Kerrie Brady

Pharma's Almanac

PAO-05-022-CL-06May 17, 2022
Bringing Novel Solutions to Market for Unmet Needs
Critical Care

Bringing Novel Solutions to Market for Unmet Needs

David Alvaro, Ph.D.; Leonard Mazur

Pharma's Almanac

PAO-04-022-CL-06Apr 25, 2022
A Media Platform for Cost-Effective and Scalable 2D and 3D Bioreactor MSC Expansion
Mesenchymal Stem Cells

A Media Platform for Cost-Effective and Scalable 2D and 3D Bioreactor MSC Expansion

David Alvaro, Ph.D.

Pharma's Almanac

PAO-04-022-CL-05Apr 21, 2022
mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?
Column: Technology

mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?

Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.; Danielle Alvarez

Pharma's Almanac

PAO-03-022-NI-02Mar 23, 2022
1 / 6